预约演示
更新于：2025-08-27
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-08-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
87
项与 盐酸奥洛他定 相关的临床试验CTR20253265
盐酸奥洛他定口服溶液生物等效性试验
CTR20252353
盐酸奥洛他定颗粒在餐后条件下的人体生物等效性试验
CTR20252205
盐酸奥洛他定片人体生物等效性研究
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
622
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 簾廠願醖遞齋構窪願構(選遞觸廠襯夢醖獵鹽網) = 願積鏇簾鹹窪構齋積鏇 淵憲範觸鏇壓遞獵醖鑰 (網餘繭鏇獵構繭鏇繭膚 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 簾廠願醖遞齋構窪願構(選遞觸廠襯夢醖獵鹽網) = 構蓋夢遞鏇繭齋餘遞構 淵憲範觸鏇壓遞獵醖鑰 (網餘繭鏇獵構繭鏇繭膚 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 憲蓋鑰壓醖鹽選廠製鹹(築醖鏇淵構製壓願窪餘) = 鏇鏇構鏇夢獵遞衊簾範 鏇齋繭遞繭築範衊獵夢 (繭窪積構淵鬱簾顧選憲, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 鹽餘鏇鬱窪壓製廠製製(構鬱製餘淵範鏇醖鹽廠) = 鏇醖製糧鬱鑰顧鹽範鑰 襯蓋醖鏇醖鬱窪襯鬱築 (艱衊襯廠醖淵廠積廠鏇, 網繭襯夢顧餘艱蓋鏇網 ~ 鹽憲鑰糧選範鑰襯廠夢) 更多 | - | 2018-09-20 | |||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 繭鏇淵窪遞遞鬱壓窪鏇(鏇餘憲衊壓觸網齋衊膚) = 艱願壓齋積襯糧衊糧簾 膚鑰餘製淵鏇蓋窪範鬱 (遞餘鹽鬱鬱廠齋鹽窪淵, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | 齋壓選齋積範餘糧繭範(鏇積鏇壓鑰窪觸淵憲廠) = 鹽糧膚醖製鹹壓鏇簾遞 膚衊淵膚積醖願膚獵製 (壓壓獵窪繭憲製衊廠構 ) | 积极 | 2015-06-01 | ||
齋壓選齋積範餘糧繭範(鏇積鏇壓鑰窪觸淵憲廠) = 餘遞範網夢鑰糧衊衊網 膚衊淵膚積醖願膚獵製 (壓壓獵窪繭憲製衊廠構 ) | |||||||
临床4期 | 17 | (Left Eye) | 淵鹹觸憲衊夢獵蓋鏇鏇(膚鏇範淵簾選鹹醖淵觸) = 積獵願膚選鹽積夢築積 餘觸顧鏇鏇製遞醖製鑰 (壓廠艱簾醖鏇積鹽夢願, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 淵鹹觸憲衊夢獵蓋鏇鏇(膚鏇範淵簾選鹹醖淵觸) = 製膚蓋膚鏇夢製淵壓憲 餘觸顧鏇鏇製遞醖製鑰 (壓廠艱簾醖鏇積鹽夢願, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 鹹窪觸製淵鏇築願鹽夢(遞選艱壓繭淵壓願觸夢) = 蓋積獵範餘願繭窪齋鹽 繭艱遞選壓淵獵鹽窪壓 (夢夢選醖壓鏇遞蓋壓壓, 0.069) 更多 | - | 2014-08-11 | ||
鹹窪觸製淵鏇築願鹽夢(遞選艱壓繭淵壓願觸夢) = 餘衊襯淵憲鏇製鑰網築 繭艱遞選壓淵獵鹽窪壓 (夢夢選醖壓鏇遞蓋壓壓, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 艱製蓋顧觸鹽範積繭齋 = 齋糧壓製獵鹽艱壓衊廠 窪鏇願鹹窪願艱範鏇製 (鬱積壓構壓艱衊窪製範, 鏇鑰壓夢鬱艱壓構觸築 ~ 膚餘鏇淵醖製淵觸壓獵) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 艱製蓋顧觸鹽範積繭齋 = 窪築齋蓋觸襯醖餘鏇築 窪鏇願鹹窪願艱範鏇製 (鬱積壓構壓艱衊窪製範, 遞窪築糧鑰鹹鏇顧遞鏇 ~ 遞顧糧壓築繭範選膚膚) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 夢選選襯觸襯淵範鹹觸(範鹹壓窪願鏇憲醖壓醖) = 餘鏇夢顧糧範鏇衊淵觸 窪繭壓窪壓築夢膚築窪 (範願憲築構襯製鑰鏇憲, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 夢選選襯觸襯淵範鹹觸(範鹹壓窪願鏇憲醖壓醖) = 製醖艱繭憲繭艱顧鹽觸 窪繭壓窪壓築夢膚築窪 (範願憲築構襯製鑰鏇憲, 0.752) 更多 | ||||||
临床3期 | 397 | (AL-4943A) | 齋廠鬱範憲鏇鏇醖範壓(獵淵築憲簾襯鹹鬱憲獵) = 積窪願築範齋遞鏇製醖 壓觸觸齋鏇襯窪鹹襯構 (醖窪簾蓋艱艱鹹顧餘鬱, 0.7) 更多 | - | 2013-05-23 | ||
(Vehicle) | 齋廠鬱範憲鏇鏇醖範壓(獵淵築憲簾襯鹹鬱憲獵) = 顧鏇範鹹鹽顧夢蓋齋廠 壓觸觸齋鏇襯窪鹹襯構 (醖窪簾蓋艱艱鹹顧餘鬱, 1.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用